Staphylococcus Aureus Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Micreos Pharmaceuticals announces success of its XZ.700 technology in selectively eliminating Staphylococcus aureus pathogen without triggering resistance
ZUG, Switzerland, April 14, 2022. Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in selectively targeting and killing the harmful Staphylococcus aureus bacterial... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 14, 2022 Category: Pharmaceuticals Source Type: clinical trials

Staphylococcus Aureus Network Adaptive Platform Trial
Condition: Staphylococcus Aureus Bacteremia Interventions: Drug: Cefazolin; Drug: Penicillin; Drug: Clindamycin; Drug: Vancomycin; Other: Effectiveness of early switch to oral antibiotics Sponsors: University of Melbourne; Menzies School of Health Research; Berry Consultants; Sunnybrook Health Sciences Centre; Tan Tock Seng Hospital; Telethon Kids Institute; The Peter Doherty Institute for Infection and Immunity; The University of Queensland; Queen sland University of Technology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2021 Category: Research Source Type: clinical trials